AQST - Aquestive Therapeutics Inc Debt to Book Capitalization Ratio

Aquestive Therapeutics (AQST) is protected by patents for its innovative PharmFilm drug delivery system while navigating stringent FDA oversight. The business's environmental focus is based on reducing plastic through the use of thin films. The visualization of the company's market value stands at 0.00. The enterprise is currently optimizing its raw material supply chains by engaging regional counterparties to eliminate transport disruptions and stabilize production output.

This indicator measures the degree of the business's reliance on borrowed funds relative to equity, determining the vulnerability of Aquestive Therapeutics (AQST) to financial shocks and the cost of servicing obligations. A stable financing structure—debt to book capitalization—confirms the resource base for developing a unique rapid-delivery drug system, allowing the investor to assess the balance between the company's debt load and its investment potential.